

Spyros I Siakavellas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1541540/publications.pdf>

Version: 2024-02-01

31
papers

1,159
citations

430874

18
h-index

477307

29
g-index

32
all docs

32
docs citations

32
times ranked

2044
citing authors

#	ARTICLE	IF	CITATIONS
1	The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. <i>Hepatology</i> , 2017, 66, 1444-1453.	7.3	239
2	Circulating levels of TNF-like cytokine 1A (TL1A) and its decoy receptor 3 (DcR3) in rheumatoid arthritis. <i>Clinical Immunology</i> , 2008, 129, 249-255.	3.2	97
3	Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. <i>Journal of Hepatology</i> , 2018, 68, 1129-1136.	3.7	88
4	Changing Pattern in the Clinical Presentation of Pediatric Celiac Disease: A 30-Year Study. <i>Digestion</i> , 2009, 80, 185-191.	2.3	76
5	High intestinal and systemic levels of decoy receptor 3 (DcR3) and its ligand TL1A in active ulcerative colitis. <i>Clinical Immunology</i> , 2010, 137, 242-249.	3.2	68
6	Immunological Characteristics of Colitis Associated with Anti-CTLA-4 Antibody Therapy. <i>Cancer Investigation</i> , 2017, 35, 443-455.	1.3	67
7	Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2017, 23, 7387-7396.	3.3	59
8	The TL1A/DR3/DcR3 pathway in autoimmune rheumatic diseases. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 1-8.	3.4	46
9	Significance of definitions of relapse after discontinuation of oral antivirals in HBeAg-negative chronic hepatitis B. <i>Hepatology</i> , 2018, 68, 415-424.	7.3	45
10	Markers of bacterial translocation in end-stage liver disease. <i>World Journal of Hepatology</i> , 2015, 7, 2264.	2.0	45
11	Differential expression of the TL1A/DcR3 system of TNF/TNFR-like proteins in large vs. small intestinal Crohn's disease. <i>Digestive and Liver Disease</i> , 2012, 44, 30-36.	0.9	41
12	Tumor Necrosis Factor-like Cytokine TL1A and Its Receptors DR3 and DcR3. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1.	1.9	41
13	Predictors of response to anti-tumor necrosis factor therapy in ulcerative colitis. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2014, 5, 293.	1.0	32
14	Comparative Study of Candidate Housekeeping Genes for Quantification of Target Gene Messenger RNA Expression by Real-Time PCR in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2840-2847.	1.9	30
15	Checkpoint inhibitor colitis. <i>Current Opinion in Gastroenterology</i> , 2018, 34, 377-383.	2.3	28
16	Evaluation of portal hypertension in the cirrhotic patient: hepatic vein pressure gradient and beyond. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 1153-1164.	1.5	26
17	Reliability and applicability of two-dimensional shear-wave elastography for the evaluation of liver stiffness. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 1204-1209.	1.6	25
18	Liver cirrhosis-effect on QT interval and cardiac autonomic nervous system activity. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2018, 9, 28-36.	1.0	24

#	ARTICLE	IF	CITATIONS
19	Systematic Review with Network Meta-Analysis: Efficacy of Induction Therapy with a Second Biological Agent in Anti-TNF-Experienced Crohn's Disease Patients. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-9.	1.5	16
20	Systemic levels of human β -defensin 1 are elevated in patients with cirrhosis. <i>Annals of Gastroenterology</i> , 2016, 29, 63-70.	0.6	16
21	Atypical Mycobacterial Infection Presenting as Persistent Skin Lesion in a Patient with Ulcerative Colitis. <i>Case Reports in Medicine</i> , 2011, 2011, 1-4.	0.7	10
22	Strongyloides hyperinfection syndrome presenting as enterococcal meningitis in a low-endemicity area. <i>Virulence</i> , 2010, 1, 468-470.	4.4	9
23	Early ileocolonoscopy with biopsy for the evaluation of persistent post-transplantation diarrhea. <i>World Journal of Gastroenterology</i> , 2010, 16, 3834.	3.3	8
24	Elevated Serum Levels of the Antiapoptotic Protein Decoy-Receptor 3 Are Associated with Advanced Liver Disease. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2016, 2016, 1-8.	1.9	6
25	One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment. <i>Hepatology International</i> , 2021, 15, 105-113.	4.2	6
26	Predictors of Response to Vedolizumab in Patients with Ulcerative Colitis: Results from the Greek VEDO-IBD Cohort. <i>Digestive Diseases and Sciences</i> , 2022, 67, 1007-1017.	2.3	4
27	Monitoring and comorbidities in patients with chronic hepatitis B currently treated with nucleos(t)ide analogs. <i>Annals of Gastroenterology</i> , 2020, 34, 73-79.	0.6	4
28	Platelet activation and hypercoagulability in patients with early primary biliary cholangitis compared with healthy controls. <i>Annals of Gastroenterology</i> , 2021, 34, 229-234.	0.6	2
29	Decoy receptor 3: Its role as biomarker for chronic inflammatory diseases. <i>World Journal of Immunology</i> , 2013, 3, 44.	0.5	1
30	Controversial Issues in Current Treatment of Chronic HBV Infection. <i>Current Hepatology Reports</i> , 2015, 14, 164-170.	0.9	0
31	Correlation of Impedance Threshold Device use during cardiopulmonary resuscitation with post-cardiac arrest Acute Kidney Injury. <i>American Journal of Emergency Medicine</i> , 2017, 35, 846-854.	1.6	0